Format

Send to

Choose Destination
See comment in PubMed Commons below
J Oncol Pharm Pract. 2014 Feb;20(1):3-10. doi: 10.1177/1078155212472702. Epub 2013 Feb 22.

Newer developments in the immunotherapy of malignant melanoma.

Author information

  • 1Department of Medicine, Yale University School of Medicine, New Haven, CT, USA.

Abstract

Individuals with malignant melanoma present a variety of immune abnormalities including but not limited to cellular immune dysfunction, antigen presentation deficits, and cytokine production defects. Therefore, enhancing the immune system potential represents an appealing avenue for melanoma therapy. The authors review the immune therapies currently in clinical use as well as the most promising immunotherapy candidates. Ipilimumab, a monoclonal antibody against the CTLA-4, was approved for the therapy of advanced melanoma in 2011. In addition, sizeable anti-melanoma activity has recently been shown with the use of other agents including anti-PD-1/anti-PD-1 ligand antibodies. Consequently, these experimental immunotherapy agents may soon become important items in the anti-melanoma armamentarium.

KEYWORDS:

Malignant melanoma; anti-CTLA-4 antibodies; anti-PD-1 antibodies; immunotherapy; ipilimumab

PMID:
23435643
DOI:
10.1177/1078155212472702
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center